TNFSF11 and breast carcinoma: To explore whether RANKL might function as a molecular link between EMT and breast cancer stemness, the RANKL-targeting activity of denosumab was studied against the background of the landmark observation that breast cancer cells experimentally induced into EMT dramatically increase the proportion of proliferative CSC-like cells, serving as a valuable screening platform for identifying agents specifically targeting CSCs [22, 23].